Navigation Links
New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association
Date:3/2/2010

NASHVILLE, Tenn., March 2 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that data from a recent study evaluating the safety and efficacy of Caldolor® (ibuprofen) Injection in treating pain and fever in hospitalized burn patients will be presented at the 42nd Annual Meeting of the American Burn Association in Boston.

The new data will be displayed in a poster presentation on Wednesday, March 10, from 12:15 p.m. to 1:15 p.m. ET. The study, entitled "A Multi-Center, Randomized, Double-Blind Trial of Ibuprofen Injection for the Treatment of Fever and Pain in the Burn Patient," will be presented by Dr. John T. Promes, Associate Director for Surgical Education at Orlando Regional Medical Center, Assistant Professor of Surgery at the University of Central Florida College of Medicine, and Clinical Assistant Professor in the Department of Surgery at the Florida State University College of Medicine.

Concurrent with the presentation on March 10th, the poster will be available on Cumberland Pharmaceuticals' website at http://investor.shareholder.com/cpix/events.cfm. Copies may also be obtained by contacting the Company at 615-255-0068.

The American Burn Association has more than 3,500 members in the United States, Canada, Europe, Asia, and Latin America. Members include physicians, nurses, occupational and physical therapists, researchers, social workers, firefighters, and hospitals with burn centers who are dedicated to promoting and supporting burn-related research, education, care, rehabilitation, and prevention. For more information, please visit www.ameriburn.org.

About Caldolor

Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, and for the reduction of fever in adults. It is the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor. For full prescribing information, including boxed warning, visit www.caldolor.com.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning and Kristalose® (lactulose) for Oral Solution, a prescription laxative. The Company also recently launched Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company completed the initial public offering of its common stock in August 2009. For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com.

SOURCE Cumberland Pharmaceuticals Inc.

Back to top

RELATED LINKS
http://www.cumberlandpharma.com

'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. Study, meta-analysis examine factors associated with death from heatstroke
5. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
6. Study says COPD testing is not measuring up
7. Preclinical study suggests organ-transplant drug may aid in lupus fight
8. Ability to cope with stress can increase good cholesterol in older white men, study finds
9. High alcohol consumption increases stroke risk, Tulane study says
10. Mailman School of Public Health study examines link between racial discrimination and substance use
11. Pitt study finds inequality in tobacco advertising
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... FL (PRWEB) , ... February 06, 2016 , ... ... pleased to announce the launch of a new DRTV campaign with Belly Bands. , ... having tried everything from sprays to puppy pads and find nothing works, get ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... company's lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider capability to ... design and manufacturing not only reduce the weight of the unit, they also ...
(Date:2/5/2016)... ... February 05, 2016 , ... The ... Popeyes Louisiana Kitchen restaurants, launched the 14th annual “Appetite for a Cure” campaign ... with muscular dystrophy, ALS and related diseases that severely limit strength and mobility. ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active staff ... plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division of ... his first three-year term as chief and began a second three-year term in January ...
(Date:2/5/2016)... , ... February 05, 2016 , ... The American public ... such water may be safer than regular municipal or well water. The recent experience ... host Sharon Kleyne, could go a long way toward increasing public acceptance of recycled ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: HSIC ... and services to office-based dental, animal health and medical ... agreement to acquire a majority ownership interest in Dental ... in Brazil . ... Dental Cremer is the dental distribution business of Cremer ...
(Date:2/5/2016)... , February 4, 2016 France , ... Spain , UK, and Israel ). It includes ... 2, and 3 GD, segmented by age and sex in these markets. ... The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert ... , Germany , Italy , ...
(Date:2/4/2016)... Ohio , Feb. 4, 2016 For ... Program, or those already participating in the program, the ... often referred to as the , Mega-Guidance , could ... final guidance is published in September 2016. ... Product and Service Marketing , summarizes the Mega-Guidance,s key ...
Breaking Medicine Technology: